Disease relevance of Rigevidon

• In order to examine whether anti-androgen therapy was effective in hidradenitis suppurativa (HS), ethinyloestradiol 50 micrograms/cyproterone acetate 50 mg in a reverse sequential regimen was compared with ethinyloestradiol 50 micrograms/norgestrel 500 micrograms (Eugynon 50) in 24 female patients [1].
• Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients [2].
• In the examined cases Anteovin of higher oestrogen content provoked more vascular cephalalgias than Rigevidon with it's lower oestrogen content [3].
• A triphasic oral contraceptive Trigynon (Schering) or Triphasil (Wyeth) was administered to 13 anovulatory women with hyperandrogenism, enlarged polycystic ovaries and reversal of LH/FSH ratio [4].
• However, significantly fewer subjects reported breakthrough bleeding (with or without spotting) in the Femodene group (18% of patients) compared with the Microgynon-30 group (26% of patients) [5].

Psychiatry related information on Rigevidon

• There were no pill failures in women taking either preparation with one exception in the Microgynon 30 group which was due to poor patient compliance [6].

High impact information on Rigevidon

• Neogynon users' performances on the Color Words Test (a measure of automatization ability) worsened and their anger, vigor and tension scores had decreased to a greater extent than was the case for members of the other groups [7].
• FVII activity increased in both groups, achieving statistical significance (P less than 0.01) by cycle 6 in the SHD 415G group but not in the females receiving Logynon [8].
• Ethinyl estradiol-desogestrel increased the concentration (+175%) and binding capacity (+330%) of sex hormone-binding globulin to a much greater extent than with ethinyl estradiol-levonorgestrel (+92% and +160%) [9].
• The influence of Microgynon and Diane-35, two sub-fifty ovulation inhibitors, on voice function in women [10].
• The pharmacokinetics of levonorgestrel (LNG) and ethinylestradiol (EE2) were determined in 9 healthy women (age 23 to 42 years), during a treatment period of three months with a low-dose oral contraceptive, containing 0.15 mg LNG together with 0.03 mg EE2 (Microgynon) [11].

Biological context of Rigevidon

• Metabolic effects of the triphasic oral contraceptive Trigynon [12].
• One woman who had taken 7 days of Trinordiol (Group 1) showed a rise of plasma levels of P to 6.8 nmol/l, but luteinization did not occur in any of the remaining 35 women who took Trinordiol or Microgynon [13].
• Target specific examinations on the haemostasis and lipid metabolism influencing effect of Anteovin are mentioned [14].
• The effects of menstruation and Microgynon 30 on sway behaviour [15].
• Both the mean body weight and blood pressure of the study subjects remained unchanged after 9 months continuous use of femenal for contraception [16].

Anatomical context of Rigevidon

• Triphasic oral contraceptive (Logynon) induced a significant increase (36%) in the maximal binding capacity of platelet membranes for [3H]imipramine [17].
• The difference of the mean CP concentration in the erythrocytes before and after taking Stediril was not statistically significant at the level of 5% [18].
• Examination of the effect of Anteovin tablet on the endometrium [19].
• Aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, and alkaline phosphatase activities in the blood serum of women taking the oral contraceptive preparation Microgynon through extended periods were raised; the activity of cholinesterase was simultaneously reduced [20].

Associations of Rigevidon with other chemical compounds

• Lipoprotein fractions showed favourable changes in Triquilar and Marvelon users with significant rise in HDL fractions at 6 and 12 months; Microgynon 30 users had equivocal changes in HDL fractions [21].
• Apolipoprotein A-II levels increased during Ministat treatment from 50.4 to 61.4 mg/dL and during Stediril-d 150/30 treatment from 52.7 to 58.9 mg/dL (both P less than 0.001) [22].
• The possibility of escape ovulation in women using a fluoroquinolone ofloxacin for antibacterial treatment at a dose of 200 mg twice daily for 7 days when taking a combined oral contraceptive (Microgynon, 150 micrograms levonorgestrel and 30 micrograms ethinyl estradiol) was studied in 20 women [23].
• The efficacy, cycle-control and tolerance of Microgynon-30, a widely prescribed levonorgestrel containing oral contraceptive, and Femodene, a new oral-contraceptive containing gestodene, were compared in a randomised, double-blind study involving 456 healthy women over a 6 month period [5].

Gene context of Rigevidon

• Increases in SHBG levels were found in the order Marvelon > Trinordiol > Gynatrol [24].
• Except Anteovin all contraceptives significantly enhanced alpha 1-antitrypsin while alpha 2-macroglobulin levels, remained nearly the same as the control values [25].

Analytical, diagnostic and therapeutic context of Rigevidon

• Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol [26].
• Despite the small sample size, the main finding in the trial is clear-cut; Loestrin-20 provides poor cycle control and is thus less acceptable as an oral contraceptive than Microgynon-30 [27].
• On stopping Microgynon, ovarian ultrasonography was carried out, in addition to blood sampling, to monitor any follicular growth [28].

References